While KRAS G12C mutations have shown promise for targeted treatment with the KRAS inhibitor Sotorasib in lung cancer, resistance to the therapy develops rapidly [30], and there are currently no clinically approved inhibitors available to target KRAS G12D, the most frequent KRAS mutation identified in CRCs. Here, KRAS is linked to lung cancer.